A phase III, randomized, multicenter, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimens of GW433908 [fosamprenavir]/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 weeks in protease inhibitor experienced HIV-infected adults experiencing virological failure

Trial Profile

A phase III, randomized, multicenter, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimens of GW433908 [fosamprenavir]/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 weeks in protease inhibitor experienced HIV-infected adults experiencing virological failure

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2005

At a glance

  • Drugs Fosamprenavir; Lopinavir/ritonavir; Ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top